HIP RESURFACING ARTHROPLASTY: FIVE-YEAR OUTCOMES IN PATIENTS AGED FIFTY YEARS OR YOUNGER

Introduction Hip Resurfacing Arthroplasty (HRA) has been performed in the United States for over 10 years and is an alternative to standard Total Hip Arthropastly (THA). It is appealing to younger patients with end stage osteoarthritis who seek to maintain active lifestyles. Benefits of HRA versus THR include a larger femoral ball size, potential to return to impact activities, decreased dislocation rates, and restoration of normal hip biomechanics. Patients ≤50 years old are a particularly challenging patient group to treat with THA because of their young age and high activity level, and as such, are well-suited for HRA. However, there are limited reports in the literature about clinical, radiographic and functional outcomes for this patient cohort. We present results of a clinical investigation at our institution for this patient cohort with minimum 5-year follow up, including long term survivorship and outcome scores. Methods HRA, using the Birmingham Hip Resurfacing (BHR), was performed for 538 procedures between 2006–2009 by a single surgeon at a United States teaching hospital. After Institutional Review Board approval, medical and radiographic study records were retrospectively reviewed. Harris Hip Scores (HHS) were routinely collected. Patients who had not returned for follow-up examination were contacted by telephone for information pertaining to their status and implant, and a modified HHS was also administered. A Kaplan Meier survival curve was constructed to evaluate time to revision. Statistical analysis was performed (SAS version 9.3; SAS Institute, Cary, NC). Results Of the 538 patients who underwent HRA from 2006–2009, 238 were aged ≤50 years (44%). Five-year follow up data was obtained from 209 of these patients (88%), using medical record documentation, and telephone survey as needed. The mean follow-up for all patients was 6 years (range 5–8 years). A total of 3% ( 8 / 238 ) were revised. Reasons included: (i) femoral loosening in 4, (ii) Iliopsoas impingement in 1, (iii) metallosis/adverse tissue reaction in 1, (iv) femoral neck fracture following motor vehicle accident in 1, and (v) unknown reasons in 1. Of the 238 patients, 55 (23%) were female, 2 ( 2 / 55 ; 3.6%) of whom have since undergone revision surgery for either metallosis/adverse tissue reaction, or unknown reasons. Of the 53 women who retained their BHR at 5-year follow up, the average HHS was 96.5. Of the 238 patients, 183 (77%) were male patients, 6 (6/183; 3.2%) of whom have since undergone revision surgery for femoral component loosening, iliopsoas impingement, or femoral neck fracture sustained in a motor vehicle accident. At 5-year follow-up, 177 male patients retained their implant and had an average Harris Hip Score of 98.8. The overall implant survival was 96.6% at approximately 5 years. Conclusion In our cohort of patients aged ≤50 treated with BHR [Fig. 1], our results demonstrated 5-year survivorship of 96.6%, with average HHS of 98.8 in males and 96.5 in females. This study demonstrates HRA is a successful alternative to traditional THA in a challenging cohort of younger, active patients.